Eton Pharmaceuticals (NASDAQ:ETON) Raised to “Strong-Buy” at B. Riley

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by analysts at B. Riley to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright upped their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, January 6th.

Eton Pharmaceuticals Trading Up 11.9 %

Shares of Eton Pharmaceuticals stock opened at $13.44 on Thursday. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00. The company has a market cap of $350.13 million, a P/E ratio of -61.09 and a beta of 1.38. The company’s fifty day simple moving average is $11.64 and its two-hundred day simple moving average is $7.35.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals during the third quarter worth about $54,000. Jane Street Group LLC purchased a new position in shares of Eton Pharmaceuticals during the third quarter valued at approximately $90,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares during the last quarter. Finally, Stonepine Capital Management LLC bought a new position in Eton Pharmaceuticals during the 2nd quarter valued at approximately $362,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.